393 results on '"Vandewalle, B."'
Search Results
2. EPH119 Disease Burden and Cost-of-Illness of Hepatocellular Carcinoma in Portugal: A Model-Based Analysis Considering the Barcelona Clinic Liver Cancer Disease Staging and Treatment Algorithm System
3. HTA232 A Multi-Criteria Decision Analysis Framework for the Value Assessment of First-Line Treatment of Adult Patients with Advanced Anaplastic Lymphoma Kinase Positive Non-Small Cell Lung Cancer
4. Statistical Analysis of Catastrophic Events
5. A Robust Estimator of the Tail Index Based on an Exponential Regression Model
6. POSC267 Atezolizumab + Bevacizumab Versus Other Systemic Therapies for the First Line Treatment of Unresectable Hepatocellular Carcinoma: A Systematic Literature Review and Indirect Treatment Comparison
7. A matching‐adjusted indirect comparison in patients with severe haemophilia A: Comparing the efficacy and consumption of rVIII-SingleChain vs two recombinant FVIII
8. 1,25-dihydroxyvitamin D3 protects human pancreatic islets against cytokine-induced apoptosis via down-regulation of the fas receptor
9. Social and Economic Value of Portuguese Community Pharmacies in Health Care
10. A robust estimator for the tail index of Pareto-type distributions
11. Non-esterified fatty acids are deleterious for human pancreatic islet function at physiological glucose concentration
12. PND58 Multiple Sclerosis in Portugal - Clinical and Economic IMPACT of Ocrelizumab
13. PCV100 Real-World IMPACT of Sacubitril/Valsartan on the Quality of Life of Heart Failure Patients in Portugal
14. On univariate extreme value statistics and the estimation of reinsurance premiums
15. Expression of peroxisome proliferator-activated receptor γ (PPARγ) in normal human pancreatic islet cells
16. Acute Insulin Response to Arginine in Deceased Donors Predicts the Outcome of Human Islet Isolation
17. Calcium regulation of heparan sulfate proteoglycans in breast cancer cells
18. Hepatocyte Nuclear Factor 4[alpha] Isoforms Originated from the P1 Promoter Are Expressed in Human Pancreatic [beta]-Cells and Exhibit Stronger Transcriptional Potentials than P2 Promoter-Driven Isoforms
19. Functionalβ-adrenergic receptors in breast cancer cells
20. Kinetics of diabetes-associated autoantibodies after sequential intraportal islet allograft associated with kidney transplantation in type 1 diabetes
21. PMU79 TWO YEARS OF A HOSPITAL-WIDE FULLY INTEGRATED BIOSIMILARS UTILIZATION MANAGEMENT SYSTEM: AN EFFICIENCY ANALYSIS
22. PNS230 CALL FOR EFFECTIVE GUIDANCE: ASSESSMENT OF PHARMACOTHERAPEUTIC GUIDELINES IMPLEMENTATION
23. PNS253 IS THERE STILL A REASON TO ARGUE FOR HIGHER DECISION-MAKING EFFICIENCY WITH SINATS? UPDATED ANALYSIS
24. PNS210 NATIONAL HEALTH TECHNOLOGY SYSTEM (SINATS) IN PORTUGAL: 4-YEAR LANDMARK ANALYSIS
25. PNS245 SNAPSHOT OF EARLY ACCESS PROGRAMMES IN PORTUGAL: A NEW ACCESS HURDLE?
26. PB2247 ADJUSTED INDIRECT COMPARISON OF ELTROMBOPAG RELATIVE TO RITUXIMAB OR SPLENECTOMY IN SECOND LINE TREATMENT FOR CHRONIC IMMUNE THROMBOCYTOPENIC PURPURA
27. 4CPS-138 Biosimilars’ utilisation under hospital pharmacy management policy
28. 1ISG-030 Biologics utilisation and its efficiency through a hospital pharmacy centralised management system
29. PHP159 - PUBLIC HEALTH AND ECONOMIC VALUE OF A NATIONWIDE PATIENT BLOOD MANAGEMENT PROGRAM
30. PIN85 - TENOFOVIR ALAFENAMIDE’S IMPACT ON COMORBIDITIES AMONG PEOPLE LIVING WITH HIV IN PORTUGAL: A SIMULATION STUDY
31. PHP96 - TIME EFFICIENCY IN THE REGULATORY DECISION-MAKING PROCESS OF ORPHAN DRUGS
32. PRM200 - STATED PREFERENCES FOR APPROPRIATE CHARACTERISTICS OF CURRENT HEPATITIS C TREATMENT REGIMENS
33. PGI37 - UNIVERSAL ACCESS TO DIRECT-ACTING ANTIVIRALS FOR THE TREATMENT OF HEPATITIS C MANAGED BY THE HOSPITAL PHARMACY: CONTRIBUTIONS TO PUBLIC HEALTH AND PUBLIC EXPENDITURE
34. PMS68 - HOSPITAL PHARMACY CENTRALIZED PROCESS FOR HOSPITAL-WIDE MANAGEMENT OF BIOSSIMILARS USE AND ITS EFFICIENCY
35. PIN87 - PHYSICIAN PREFERENCES FOR THE TREATMENT OF CHRONIC HEPATITIS C VIRUS INFECTION: AN ADAPTIVE CONJOINT ANALYSIS
36. PHP299 - THREE YEARS OF SINATS
37. PCV89 - CLINICAL AND ECONOMIC BURDEN OF IRON DEFICIENCY IN PATIENTS WITH CHRONIC HEART FAILURE
38. PCN145 - COST-EFFECTIVENESS OF NINTEDANIB FOR THE TREATMENT OF NON-SMALL LUNG CANCER IN PORTUGAL
39. PHP280 - IS THERE A REASON TO ARGUE FOR HIGHER DECISION-MAKING EFFICIENCY WITH SINATS?
40. PHP52 - ACCESSIBILITY AND ACCESS TO ORPHAN DRUGS IN PORTUGAL: HOW FAR ARE WE?
41. PHP114 - THE ERRATIC AND LONG ACCESS JOURNEY OF ORPHAN DRUGS FROM EUROPE TO PORTUGAL
42. PHP110 - SUBSTANTIAL HEALTH GAINS FROM HEATH-SYSTEM-WIDE PATIENT BLOOD MANAGEMENT IMPLEMENTATION: ANALYTICS FOR EUROPE
43. PIN72 - HEALTHCARE RESOURCE UTILIZATION AND COSTS ASSOCIATED TO THE MANAGEMENT OF CHRONIC HEPATITIS C VIRUS INFECTION IN PORTUGAL
44. PMS6 - EFFECTIVENESS OF BIOSSIMILARS UNDER HOSPITAL PHARMACY MANAGEMENT POLICY
45. PRM134 - USING ADJUSTED INDIRECT COMPARISON IN HTA TO OVERCOME SHORT FOLLOW-UP TIME IN REGULATORY RANDOMIZED CONTROLED CLINICAL TRIALS: RIBOCICLIB AS FIRST-LINE THERAPY FOR HR-POSITIVE, ADVANCED BREAST CANCER
46. Hospital Pharmacy Management Of Access To Direct-Acting Antivirals For The Treatment Of Hepatitis C And Its Contribution To Public Health And Economic Efficiency – A Single-Center Experience
47. Delaying Second Line Diabetes Treatment Onset In Patients Uncontrolled With Metformin Xr In Saudi Arabia: Cost-Effectiveness Analysis
48. Metformin Extended Versus Immediate Release In Saudi Arabia: A Cost-Effectiveness Analysis
49. A Model-Based Meta-Analysis For The Effect of Metformin On Hba1c Levels In Patients With Type-2 Diabetes Mellitus
50. Cost-Effectiveness of Trifluridine/Tipiracil for The Treatment of Metastatic Colorectal Cancer in Portugal
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.